SGN-CD352A / Pfizer - LARVOL DELTA

Seattle Genetics reports second quarter 2016 financial results (Seattle Genetics Press Release) -  "Anticipated pipeline programs upcoming activities: [1] Initiate a phase 1 trial of SGN-CD123A in relapsed or refractory AML; [2] Advance SGN-CD352A, a novel ADC for multiple myeloma, into a phase 1 clinical trial. SGN-CD352A targets CD352, and utilizes the company’s PBD and EC-mAb technology."

Anticipated new P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Multiple Myeloma • Oncology

A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1; N=27; Terminated; Sponsor: Seattle Genetics, Inc.; Trial completion date: Dec 2019 ➔ Jul 2019; Active, not recruiting ➔ Terminated; Trial primary completion date: Dec 2019 ➔ Jul 2019; Sponsor decision based on portfolio prioritization

Clinical • Trial completion date • Trial primary completion date • Trial termination

A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1; N=27; Active, not recruiting; Sponsor: Seattle Genetics, Inc.; Trial primary completion date: Dec 2018 ➔ Dec 2019

Clinical • Trial primary completion date